Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe page has undergone significant content changes, particularly the removal of detailed information about gastric cancer treatments and the addition of a new study on pembrolizumab in combination with trastuzumab for HER2 positive gastric cancer. Additionally, the revision number has been updated.SummaryDifference33%
- Check65 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check101 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.